^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Published date:
    09/28/2021
    Excerpt:
    First-line treatment for advanced ccRCC...Lenvatinib–pembrolizumab [I, A; ESMO-MCBS v1.1 score: 4] is now FDA-approved but not EMA-approved and joins other PD-1 inhibitor–VEGFR-targeted combinations (axitinib–pembrolizumab [I, A; ESMO-MCBS v1.1 score: 4] or cabozantinib–nivolumab [I, A; ESMO-MCBS v1.1 score: 4]) to be recommended for first-line treatment of advanced ccRCC, irrespective of the International Metastatic RCC Database Consortium (IMDC) risk groups.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    First-line therapy for clear cell histology…Preferred regimens…Lenvatinib + pembrolizumab (category 1)